Search research articles
Contact Us
Filters
Showing results (31-40 of 83) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 30, 2009
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors
Alison H M Reid, Andrew Protheroe, Gerhardt Attard, et al.
European Urology
|
December 4, 2014
SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma
Thomas Geldart, John Chester, Angela Casbard, et al.
European Urology
|
December 18, 2019
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study
Nobuaki Matsubara, Kim N Chi, Mustafa Özgüroğlu, et al.
Clinical Genitourinary Cancer
|
June 22, 2016
Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors
Karin Purshouse, Robert A Watson, David N Church, et al.
The Lancet. Oncology
|
June 30, 2014
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Karim Fizazi, Christophe Massard, Petri Bono, et al.
Carcinogenesis
|
July 11, 2012
CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC
Swethajit Biswas, Philip J S Charlesworth, Gareth D H Turner, et al.
International Journal of Molecular Sciences
|
August 26, 2023
Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types
Srinivasa R Rao, Andrew Protheroe, Lucia Cerundolo, et al.
The Lancet. Oncology
|
April 17, 2019
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Karim Fizazi, NamPhuong Tran, Luis Fein, et al.
Cold Spring Harbor Molecular Case Studies
|
May 11, 2017
Whole-genome sequencing identifies homozygous <i>BRCA2</i> deletion guiding treatment in dedifferentiated prostate cancer
Karin Purshouse, Anna Schuh, Benjamin P Fairfax, et al.
Urologic Oncology
|
July 18, 2024
Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel
Francesca Jackson-Spence, Charlotte Ackerman, Robert Jones, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 83) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 30, 2009
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors
Alison H M Reid, Andrew Protheroe, Gerhardt Attard, et al.
European Urology
|
December 4, 2014
SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma
Thomas Geldart, John Chester, Angela Casbard, et al.
European Urology
|
December 18, 2019
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study
Nobuaki Matsubara, Kim N Chi, Mustafa Özgüroğlu, et al.
Clinical Genitourinary Cancer
|
June 22, 2016
Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors
Karin Purshouse, Robert A Watson, David N Church, et al.
The Lancet. Oncology
|
June 30, 2014
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Karim Fizazi, Christophe Massard, Petri Bono, et al.
Carcinogenesis
|
July 11, 2012
CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC
Swethajit Biswas, Philip J S Charlesworth, Gareth D H Turner, et al.
International Journal of Molecular Sciences
|
August 26, 2023
Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types
Srinivasa R Rao, Andrew Protheroe, Lucia Cerundolo, et al.
The Lancet. Oncology
|
April 17, 2019
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Karim Fizazi, NamPhuong Tran, Luis Fein, et al.
Cold Spring Harbor Molecular Case Studies
|
May 11, 2017
Whole-genome sequencing identifies homozygous <i>BRCA2</i> deletion guiding treatment in dedifferentiated prostate cancer
Karin Purshouse, Anna Schuh, Benjamin P Fairfax, et al.
Urologic Oncology
|
July 18, 2024
Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel
Francesca Jackson-Spence, Charlotte Ackerman, Robert Jones, et al.
Page
of 9